德乌克拉维西提尼布对TYK2的多作用全抑制:来自计算模拟的见解
Yiqiong Bao1, Ran Xu2, Jingjing Guo3
1Department of Biomedical Informatics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Computational biology and chemistry
|October 1, 2024
概括
德乌克拉维西替尼 (DEU) 通过稳定其JH2和JH1域之间的抑制接口来全质抑制TYK2. 这种机制增强了负调节,为TYK2针对自身免疫性疾病的治疗提供了洞察力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 简氏酶信号转换器和转录激活器 (JAK-STAT) 途径在免疫反应中至关重要.
- 作为JAK家族的一员,TYK2与牛皮和多发性硬化症等自身免疫性疾病有关.
- 德乌克拉维西替尼 (DEU) 是一种经批准的口服TYK2抑制剂,在牛皮中表现出临床疗效.
研究的目的:
- 阐明Deucravacitinib (DEU) 在TYK2伪酶 (JH2) 和酶 (JH1) 域上的全抑制机制.
- 提供对DEU如何影响TYK2 JH2和JH1.1之间的相互作用的分子理解.
- 在JAK家族中为开发新型JH2向药物提供理论支持.
主要方法:
- 利用AlphaFold2来预测TYK2 JH2和JH1域的结构.
- 采用分子动力学模拟来研究全抑制机制.
- 分析了DEU结合对JH2-JH1接口和酶活性的影响.
主要成果:
- 通过调节JH2-JH1接口,DEU通过全性抑制TYK2.
- DEU结合稳定了JH2和JH1之间的自抑制接口.
- DEU破坏了激活接口的形成,增强了JH2介导的JH1负调节,并阻碍了ATP结合.
结论:
- 德乌克拉维西替尼的机制涉及稳定伪激酶域在激酶域上的自身抑制作用.
- 这些发现加深了对JAK激酶中伪激酶依赖性自身抑制的理解.
- 该研究为JH2向药物发现在JAK家族成员的自身免疫性疾病提供了强有力的理论基础.
相关概念视频
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Receptor Tyrosine Kinases
12.4K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K


